Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Starting soon Phase 3

EFFECT OF ANODAL TRANSCRANIAL DIRECT CURRENT STIMULATION ON NAMING IN APHASIC PATIENTS WITH ACUTE ISCHEMIC STROKE

NCT07496645 · tracked via the Priya Life Science India tracker
Phase
Phase 3
Started
2026-03-31
Last updated
2026-03-27

Condition(s) studied

Acute Ischemic Cerebrovascular DiseasePost Stroke AphasiaAphasia Following Cerebral InfarctionAphasia, Acquired

Investigational drug(s) / intervention(s)

Transcranial Direct Current StimulationTranscranial Direct Current Stimulation

Transcranial Direct Current Stimulation: Anodal tDCS

Transcranial Direct Current Stimulation: Sham tDCS

Study summary

The use of transcranial direct current stimulation (tDCS) for the management of deficits developed in stroke is a relatively new type of management option. Many of the studies performed using tDCS have focused on improvements noted in hemiplegia as compared to aphasia, which is an equally disabling outcome of strokes. The results of these studies have not been conclusive and concordant with each other.

In aphasia management, the majority of the studies have focused on chronic strokes. Since the use of tDCS is relatively new, the studies have not focused on a particular type of deficit or stroke. Very few studies have focused on the impact of solely using tDCS. Very few studies have focused on acute to subacute strokes. The results of the studies have, nevertheless, been encouraging.

Improvements in aspects of language tested after a single session of tDCS are short-lived. There is an unmet need to probe the utility of repetitive tDCS on aspects of language function in patients who are aphasic due to acute stroke. There is also a paucity of data in the Indian scenario regarding the same.

Eligibility

Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria: * Aphasic patients with left middle cerebral artery territory Acute Ischemic Stroke * Patients between 18-65 years of age. * Within 5 days of onset of stroke. Exclusion Criteria: * Patients with malignant Middle Cerebral Artery territory infarcts and previous clinical history of cerebral hemisphere stroke. * Patients with history of previous brain surgery or skull defect due to surgery e.g. craniectomy. * Patients with epilepsy. * Patients with history of significant head trauma in the last 1 month. * Patients with documented history of major depression prior to stroke. * Patients with alcohol/drug abuse in the past 6 months. * Patients with prior significant cognitive impairment. * Pacemaker in situ, cochlear implant in situ. * Pregnancy.

Primary outcome measure(s)

  • Primary Outcome: Difference of change in Accuracy between Anodal tDCS group and Sham tDCS group at 5 days — at 5 days after tDCS
    Accuracy is defined as the number of words spoken without the help of a semantic or phonemic cue on the ICMR Picture Naming Test
  • Co-Primary outcome: Difference of change in Reaction Time between Anodal tDCS group and Sham tDCS group at 5 days — at 5 days after tDCS
    Reaction times were documented in milliseconds.

Trial sites (1)

FacilityCityRegionStatus
Atal Bihari Vajpayee Institute of Medical Sciences and Dr. Ram Manohar Lohia Hospital, New Delhi New Delhi National Capital Territory of Delhi
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07496645 on ClinicalTrials.gov ↗ ← All trials in India